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ABSTRACT
Purpose Fractures are a recognized consequence of androgen deprivation therapy (ADT); however, less is known about the incidence of
fracture in relation to the timing of ADT use or the impact of fracture on mortality in men with prostate cancer.
Methods Using data from the Surveillance, Epidemiology, and End Results–Medicare linked database, we estimated adjusted hazard ratios
(aHRs) using time-dependent Cox regression for fracture incidence related to the recency of exposure and dose among prostate cancer
patients on gonadotropin-releasing hormone (GnRH) agonists, as well as mortality associated with fractures.
Results In our cohort of 80 844 patients, ADT was associated with an increased rate of fracture in both non-metastatic patients
(aHR = 1.34; 95% conﬁdence interval [CI] = 1.29–1.39) and metastatic patients (aHR = 1.51; 95%CI = 1.36–1.67). Fracture rates in-
creased with increasing cumulative GnRH dose but decreased with increasing number of months since last use in each dose category.
The mortality rate doubled for men experiencing a fracture after their diagnosis compared with that for men who did not experience a
fracture (aHR= 2.05; 95%CI = 1.98–2.12).
Conclusions ADT in elderly men with prostate cancer increased the incidence of fractures, and the effect appears to diminish with increas-
ing time since the last dose of a GnRH agonist. Experiencing a fracture after the diagnosis of prostate cancer was associated with decreased
survival. Copyright © 2011 John Wiley & Sons, Ltd.
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INTRODUCTION
Androgen deprivation therapy (ADT) is a common
treatment for men with metastatic prostate cancer, for
those with non-metastatic disease in combination with
radiation therapy, as well as among patients with rising
prostate-speciﬁc antigen concentrations after deﬁnitive
treatment (radical prostatectomy or radiation ther-
apy).1 With the rise in the use of ADT, there has been
increasing recognition of potentially serious adverse
effects including diabetes, cardiovascular disease,
osteoporosis, and fracture.2–5 It has been estimated
that use of gonadotropin-releasing hormone (GnRH)
agonists among men with non-metastatic prostate
cancer is associated with an annual loss of 0.6% to
4.6% in bone mineral density, with the greatest rate
of bone loss occurring during the ﬁrst year of ther-
apy.1,6–8 Several lines of treatment have been shown
to reverse ADT-related bone loss in patients with
non-metastatic prostate cancer, including bisphospho-
nates, RANK ligand monoclonal antibodies, and se-
lective estrogen receptor modulators.9–15
Although the association between ADT and fracture
risk in prostate cancer has been established, 2,3,16–18
we know much less about how this risk varies as a
*Correspondence to: J. L. Beebe-Dimmer, Department of Oncology, Wayne State
University, 4100 John R. Detroit, MI 48201, USA. E-mail: dimmerj@karmanos.org
Copyright © 2011 John Wiley & Sons, Ltd.
pharmacoepidemiology and drug safety 2012; 21: 70–78
Published online 24 November 2011 in Wiley Online Library (wileyonlinelibrary.com) DOI: 10.1002/pds.2258
function of duration of time on ADT and, for those
who discontinue therapy, how risk varies with time
since discontinuation. Furthermore, although ADT-
induced skeletal complications clearly inﬂuence the
quality of life in men with prostate cancer, a large-
scale investigation of the potential impact of experi-
encing a fracture on mortality among men with
non-metastatic disease has never been conducted.1 In
this investigation, using the most recent decade of data
available from the Surveillance, Epidemiology, and
End Results (SEER)–Medicare database, we estimate
the incidence of fracture associated with both the re-
cency of use and cumulative dose of ADT in men with
prostate cancer. In addition, we estimate the relative
risk of death among non-metastatic prostate cancer
patients who experience a fracture.
METHODS
The SEER–Medicare dataset is a unique resource
linking two population-based sources of data used
to provide information about the experience of
elderly patients with cancer in the USA. The SEER
program, sponsored by the National Cancer Insti-
tute, is a network of population-based cancer regis-
tries that routinely collects information on patients
with a new diagnosis of invasive cancer, residing
within one of the registry catchment areas. SEER
is composed of 18 statewide or regional cancer reg-
istries, collecting data on patient demographics,
tumor histology and pathology, ﬁrst course of treat-
ment, and survival. Through linking SEER registry
data to Medicare enrollment and claims ﬁles, the
SEER–Medicare database provides additional infor-
mation on treatment and outcomes of approximately
25% of elderly patients diagnosed with cancer in
the USA.19
The eligible patients for the current investigation were
diagnosed at the age of 66 years and older with primary
malignant prostate cancer (site code C61.9, International
Classiﬁcation of Diseases for Oncology 3rd Edition) be-
tween 1 January 1996 and 31 December 2003, captured
among 1 of 16 SEER registries (Connecticut, Hawaii,
Iowa, New Mexico, Utah, Atlanta, Rural Georgia,
Detroit, Seattle-Puget Sound, Los Angeles, San Jose-
Monterey, San Francisco-Oakland, Greater California,
Kentucky, Louisiana, and New Jersey). Patients not
continuously enrolled in both Part A and Part B
Medicare for the 12months prior to and following
prostate cancer diagnosis were excluded in an effort
to minimize the misclassiﬁcation of fracture as well
as other comorbidities prior to prostate cancer
diagnosis. Patients who were members of a health
maintenance organization (HMO) at any point in the
12-month period prior to and following prostate
cancer diagnosis were also excluded to avoid the po-
tential for missing information due to claims not pro-
cessed through Medicare. Patients receiving ADT
prior to prostate cancer diagnosis were excluded, as
well as patients with a fracture claim within 1 month
of cancer diagnosis and those missing important clin-
ical data, leaving a total study population of 80 844
men available for analysis (Figure 1).
Exposure to ADT was based on the documentation
of at least one dose of a GnRH agonist or orchiectomy
after prostate cancer diagnosis. To calculate GnRH
dose, we used the methods developed by one of our
coauthors (V.S.) as recommended by the National
Cancer Institute (NCI).2 Dose was calculated from
each instance of a GnRH agonist injection noted on
separate days for the 12-month period after diagnosis
as well as the total number of doses over the follow-
up period. Because GnRH agonists are administered
as depot injections with the dosage given depending
on the intended regimen (every 1, 3, and 4months),
the dosage recorded from the Medicare claims ﬁles
was then converted to a once-a-month regimen. In
addition, time (in months) since last use of a GnRH
agonist was calculated from the month of last dose to
the month of fracture or censoring.
Fracture diagnoses were identiﬁed through Inter-
national Classiﬁcation of Diseases, 9th revision
(ICD-9) codes and extracted from the Medicare
physician (carrier), inpatient, or outpatient claims
ﬁles. Fractures requiring hospitalization were ana-
lyzed separately from inpatient claim ﬁles. Patients
were followed for fracture until 31 December
2006, representing the end of complete follow-up
for patients included in SEER–Medicare. Patient
characteristics (age at diagnosis, race, and a history
of osteoporosis, osteopenia, and fracture), year of
diagnosis, disease characteristics (clinical tumor
stage and histological grade), and treatment other
than ADT (radical prostatectomy and radiation ther-
apy) were examined for their relations with fracture
incidence. We also included in our analyses a mod-
iﬁed version of the Charlson comorbidity index,
which was based on ICD-9 diagnostic and proce-
dure codes as well as on the Healthcare Common
Procedure Coding System codes for 10 conditions
captured in the 12-month period prior to prostate
cancer diagnosis for all cases.20 Ecologic measures
of socioeconomic position were also evaluated de-
scribing the education and income level of the
census tract in which the patient resided at the time
of diagnosis.21
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Statistical methods
All statistical analyses were performed using the Sta-
tistical Analysis Software (SAS Institute Inc. v. 9.1,
Cary, NC). We calculated the proportion of patients
receiving ADT as part of their treatment according to
various baseline characteristics. We estimated both
the incidence of fracture (with 95% conﬁdence inter-
vals [CIs]) for all patients combined and according to
ADT treatment, standardized to the age distribution
of non-ADT patients. Likewise, the estimated rate as-
sociated with ADT was calculated for the three most
common sites of fracture (rib, hip, and spine). Cox
proportional hazards regression was used to estimate
adjusted hazard ratios (aHRs) and 95%CIs associated
with ADT controlling for potential confounders.
ADT was treated as a time-dependent covariate (i.e.,
patients were not considered exposed until the date
of ﬁrst receipt of a GnRH agonist or orchiectomy).
The outcome was the time (in months) to fracture or
censoring. Prostate cancer patients with no fracture
claim during follow-up were censored at (i) death,
(ii) loss of or change in Medicare coverage, or (iii) 31
December 2006—whichever came ﬁrst. Final models
Patients diagnosed 1996-2003 
Primary malignant prostate carcinoma (PCa) 
Age-eligible for Medicare 
N=153,155
Missing month of diagnosis (n=993) 
No continuous coverage of Part A&B or in HMO in 
12 months prior to PCa diagnosis (n=52,953) 
N=99,209
No continuous coverage of Part A&B or in HMO in 
12 months after PCa diagnosis (n=5,330) 
N=93,879 
ADT prior to PCa diagnosis (n=874) 
N=93,005 
Fracture claim within month of PCa diagnosis 
(n=707) 
N=92,298  
Patients with both GnRH and orchiectomy claims  
 (n=774) 
 (N=91,524)
Patients with unknown grade, stage, race or primary treatment 
information in SEER (PEDSF)  
 (n=10,680) 
(N=80,844) (Table 1)
Patients with metastatic claims or distant stage 
 (N=8,452) (Tables 1-2)
Patients with non-metastatic disease (N=72,392) (Tables 1- 3)
Figure 1. Prostate cancer patients participating in SEER–Medicare study
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included age at diagnosis, race, history of fracture,
osteoporosis or osteopenia, Charlson comorbidity
index, tumor grade, stage, primary treatment (radiation
or prostatectomy), and use of intravenous (IV) bispho-
sphonates (among metastatic patients). Fracture analy-
ses were further stratiﬁed to examine ADT effects
separately among patients with and without metastatic
disease, determined from data collected from either
SEER or evidence of bone metastases extracted from
claims ﬁles. When the ﬁndings related to ADT were
similar in patients with and without metastatic disease,
we opted to present only those ﬁndings for men with
non-metastatic disease. However, when the ﬁndings
were deemed different among men with metastatic
disease, the aHRs are presented separately. To capture
the effect of the timing of ADT and the cumulative
dosage on fracture incidence, a time-dependent covari-
ate was created that took into account the time from
last treatment (TFLT) in months. The TFLT was equal
to 0 if the patient was on ADT during the month of
consideration and increased by one for each month
off treatment unless treatment resumed, in which case
TFLT once again equaled 0. This information was then
combined with the cumulative (CUM) dosage of ADT
up to the month of interest using methodology re-
commended to capture multiple characteristics of a
single exposure.22 For example, TFLT6CUM10 would
indicate 6months from the patient’s last GnRH agonist
dose, with a total of 10 doses at that particular point.
We estimated hazard ratios for each combined expo-
sure category relative to the reference group (men
without ADT). Last, we used Cox regression to esti-
mate the mortality rate associated with (i) any fracture
and (ii) fracture requiring hospitalization, treating each
as a time-dependent predictor, adjusting for potential
confounders (i.e., age, race, year of diagnosis, tumor
grade, stage, comorbidities, and primary treatment).
RESULTS
Of the 80 844 prostate cancer patients diagnosed at the
age of 66 years and older included in this investiga-
tion, 14 905 (18.4%) experienced at least one fracture
during the course of follow-up, with 3340 (4.1%) hav-
ing a fracture that required hospitalization. Nearly
53% of patients in the study received some form of
ADT after their prostate cancer diagnosis (Table 1),
with 51% of patients on GnRH agonists and 2% of
patients undergoing orchiectomy. ADT use was posi-
tively associated with age at diagnosis, with ~40% of
patients aged 66 to 69 years receiving some form of
ADT, compared with nearly 70% of patients
diagnosed at the age of 80 years and older. The preva-
lence of use varied depending upon year of diagnosis,
increasing from approximately 49% of patients diag-
nosed in 1996 to 57% of patients diagnosed in 2000,
and then declining through 2003. ADT use was more
common among patients with one or more conditions
captured by the Charlson index, among patients with
advanced stage and/or aggressive grade disease and,
as expected, among patients electing radiation therapy
as their primary treatment or no deﬁnitive treatment.
The use of IV bisphosphonates prior to fracture in this
population was low overall (2.3%) and differed by the
presence of distant metastases (0.6% in non-metastatic
patients and 18.2% in metastatic patients). This was
expected given the timing of the study period relative
to the approval of zoledronic acid by the US Food
and Drug Administration for the treatment of bone
metastases from solid tumors.23
The age-standardized incidence of fracture was
higher among ADT users than that among non-users.
The fracture rate among patients receiving at least
one dose of a GnRH agonist was 57 per 1000 persons
per year (95%CI = 56–58) compared with 31 per 1000
persons per year (95%CI = 30–32) among non-users.
The fracture rate among orchiectomy patients was 76
per 1000 persons per year (95%CI = 68–84).
Among non-metastatic patients, GnRH agonist use,
treated as a time-dependent dichotomous variable,
was associated with a 34% increase in the rate of any
fracture (HR= 1.34; 95%CI = 1.29–1.39), and a posi-
tive dose–response relation was observed between
fracture incidence and the cumulative number of
GnRH doses received over the study period (Table 2).
A slightly higher increase in fracture incidence associ-
ated with ADT use was observed among men with
metastatic disease (aHR= 1.51; 95%CI = 1.36–1.67).
Again, aHRs increased with increasing GnRH dose.
Orchiectomy was associated with a 62% increase in
risk of any fracture (aHR= 1.62; 95%CI = 1.42–1.84)
among non-metastatic patients and a 54% increase in
risk among metastatic patients (aHR= 1.54; 95%CI =
1.26–1.88). The three most common sites of ﬁrst-time
fracture among patients in the study were rib (17.5%),
hip (16.5%), and spine (14.6%), but the elevation in
incidence associated with ADT use did not differ
appreciably by site (data not shown).
Among non-metastatic patients using GnRH ago-
nists, the incidence rate of fracture was positively
associated with cumulative ADT dose and inversely
related to the number of months since last use
(Table 3). Thus, the fracture risk was highest among
patients receiving at least 18 doses of an agonist
who were either currently on or who had stopped
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therapy in the past 6months (compared with men
who had not used ADT, aHR= 1.67; 95%CI =
1.56–1.78). Conversely, the fracture risk was almost
the same for men who had received fewer than six
doses more than 18months ago and men who
had not received any ADT (aHR= 1.06; 95%CI =





ADT (%) n (%)*
Proportion on
ADT (%) n (%)*
Proportion on
ADT (%)
Total 80 844 52.8 72 392 89.5 49.9 8452 10.5 77.6
Age (in years)
66–69 20 453 25.3 39.3 18 754 25.9 36.5 1699 20.1 70.2
70–74 26 418 32.7 49.7 23 782 32.9 47.0 2636 31.2 74.0
75–79 20 256 25.1 59.8 18 049 24.9 57.2 2207 26.1 80.6
≥ 80 13 717 17.0 68.5 11 807 16.3 65.7 1910 22.6 85.7
Race
White 66 005 81.6 52.4 59 595 82.3 49.5 6410 75.8 79.2
Black 7478 9.2 50.5 6373 8.8 48.1 1105 13.1 64.3
Other 7361 9.1 58.1 6424 8.9 54.6 937 11.1 82.1
Year of diagnosis
1996 6509 8.1 49.1 5391 7.4 44.5 1118 13.2 71.3
1997 6699 8.3 50.1 5641 7.8 46.1 1058 12.5 71.4
1998 6385 7.9 52.3 5518 7.6 48.9 867 10.3 73.6
1999 6965 8.6 53.9 6084 8.4 50.4 881 10.4 78.1
2000 12 638 15.6 56.6 11 342 15.7 53.6 1296 15.3 83.0
2001 13 763 17.0 54.5 12 565 17.4 51.9 1198 14.2 81.3
2002 14 393 17.8 52.1 13 294 18.4 49.7 1099 13.0 81.4
2003 13 492 16.7 50.8 12 557 17.3 48.7 935 11.1 78.7
<12 years of education†
<10% 27 233 33.7 49.4 24 778 34.2 46.5 2455 29.0 79.3
10% to < 20% 28 312 35.0 53.6 25 385 35.1 50.7 2927 34.6 78.7
20% to < 30% 12 571 15.6 54.3 11 116 15.4 51.6 1455 17.2 74.4
≥ 30% 12 724 15.7 56.6 11 109 15.3 53.8 1615 19.1 76.0
Income below the poverty line†
<3% 12 124 15.0 51.7 10 951 15.1 48.9 1173 13.9 77.6
3% to < 7% 26 469 32.7 52.4 23 802 32.9 49.5 2667 31.6 78.4
7% to < 14% 21 762 26.9 52.6 19 591 27.1 49.7 2171 25.7 78.7
≥14% 20 485 25.3 54.0 18 044 24.9 51.1 2441 28.9 75.8
Charlson comorbidity index
0 59 617 73.7 50.9 53 429 73.8 47.8 6188 73.2 78.0
1 14 801 18.3 57.0 13 259 18.3 54.7 1542 18.2 76.0
2 4261 5.3 59.8 3792 5.2 57.4 469 5.5 79.1
+3 2166 2.7 60.4 1913 2.6 58.4 253 3.0 75.5
Grade of prostate cancer
Well differentiated 4475 5.5 35.9 4225 5.8 34.7 250 3.0 56.0
Moderately
differentiated
55 710 68.9 47.4 51 538 71.2 45.6 4172 49.4 69.7
Poorly differentiated 20 659 25.6 70.9 16 629 23.0 67.0 4030 47.7 87.1
Clinical T stage
I 30 423 37.6 45.2 28 417 39.3 43.8 2006 23.7 66.1
II 45 526 56.3 54.5 41 938 57.9 52.6 3588 42.5 76.5
III 2009 2.5 79.8 1676 2.3 77.5 333 3.9 91.6
IV 2886 3.6 85.7 361 0.5 80.1 2525 29.9 86.5
SEER summary stage
Local/Regional 78 382 97.0 51.7 72 392 100.0 49.9 5990 70.9 74.1
Distant 2462 3.0 86.2 0.0 2462 29.1 86.2
Other treatment within 6 months of diagnosis
Neither 30 035 37.2 60.8 25 512 35.2 56.6 4523 53.5 84.2
Radiation 36 545 45.2 58.1 33 421 46.2 56.6 3124 37.0 74.6
Radical
prostatectomy
13 605 16.8 20.8 12 885 17.8 19.2 720 8.5 48.6
Both 659 0.8 52.2 574 0.8 48.3 85 1.0 78.8
SEER, Surveillance, Epidemiology, and End Results; ADT, androgen deprivation therapy.
*Percentages may not sum 100% due to rounding.
†This refers to the census tract in which the patient resided at the time of diagnosis and the proportion of residents within the tract with fewer than 12 years of
education or household income below the poverty line (four missing).
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0.99–1.14). Similar trends were observed among
metastatic patients (data not shown).
Among men with non-metastatic disease, the mor-
tality risks within 6 and 12months of experiencing
any fracture were 8.3% and 12.2%, respectively. Frac-
ture was associated with a more than twofold increase
in the rate of death (aHR= 2.05; 95%CI = 1.98–2.12)
after adjusting for age at diagnosis, year of diagnosis,
race, the presence of one or more comorbidities prior
to diagnosis, tumor grade, stage, and initial treatment.
The occurrence of a fracture that required hospitaliza-
tion was associated with a nearly threefold increase in
the rate of death (aHR= 2.82; 95%CI = 2.68–2.97)
after adjusting for the same prognostic covariates.
DISCUSSION
In this large, population-based investigation of elderly
men with prostate cancer, we observed that the use of
ADT was associated with a 34% increase in fracture
incidence and that the rate increased with cumulative
dose (among men on GnRH agonists). Our results are
consistent with prior reports linking ADT to fracture in
men with prostate cancer.2,3,16 Our study is the ﬁrst to
report an inverse relationship between rate of fracture
and the time since last use of GnRH agonists. In addi-
tion, we found that fracture occurrence after prostate
cancer diagnosis was associated with excess mortality
among men with non-metastatic disease, particularly
when that fracture resulted in hospitalization.
Recent concepts about osteoporotic fracture incorpo-
rate the effect of increased bone turnover on impair-
ment of bone strength, independent of reduced bone
mineral density.24 This is supported by results of trials
of antiresorptive therapies in postmenopausal women
that demonstrated fracture risk reduction that could
not be fully explained by improvements in bone min-
eral density.25 Androgen deprivation, through the
induction of testosterone, and more importantly, estro-
gen deﬁciency, increases bone turnover and bone
resorption, eventually leading to declines in bone min-
eral density.26,27 Our ﬁndings are consistent with this
current understanding of the pathophysiology of osteo-
porotic fracture risk. The increased rate of fracture in
men receiving only a few doses of GnRH agonists,
which then returns to normal over time after discontin-
uation of therapy, may predominantly represent the
effect of androgen deprivation on bone turnover. In
Table 2. Adjusted hazard ratio* (and 95%CI) for fracture risk associated with ADT among elderly men diagnosed with prostate cancer (n= 80 844)
All fractures Fractures requiring hospitalization
Non-metastatic Metastatic Non-metastatic Metastatic
No ADT 1.00 1.00 1.00 1.00
Gonadotropin-releasing hormone agonist 1.34 (1.29–1.39) 1.51 (1.36–1.67) 1.34 (1.26–1.43) 1.58 (1.35–1.85)
1–5 doses† 1.21 (1.15–1.27) 1.22 (1.07–1.39) 1.11 (1.02–1.22) 1.12 (0.90–1.40)
6–17 doses 1.31 (1.25–1.38) 1.48 (1.31–1.68) 1.29 (1.19–1.40) 1.49 (1.24–1.81)
≥ 18 doses 1.66 (1.57–1.76) 1.99 (1.75–2.27) 1.74 (1.59–1.90) 2.20 (1.82–2.67)
Orchiectomy 1.62 (1.42–1.84) 1.54 (1.26–1.88) 1.87 (1.56–2.25) 1.63 (1.21–2.18)
CI, conﬁdence interval; ADT, androgen deprivation therapy.
*Hazard ratios were adjusted for age at prostate cancer diagnosis, race, tumor grade, clinical T stage, presence of comorbidities, history of fracture, osteopo-
rosis or osteopenia prior to prostate cancer diagnosis, and primary treatment. Analyses among metastatic patients were additionally adjusted for intravenous
bisphosphonate use.
†Cumulative dose from diagnosis until fracture or censoring event.
Table 3. Risk of fracture associated with dose and recency of GnRH agonist use among men with non-metastatic prostate cancer (n= 72 392)
Months since last GnRH agonist dose
0–6months 7–12months 13–18months ≥19months
Cumulative dose aHR (95%CI) aHR (95%CI) aHR (95%CI) aHR (%%CI)
1–5 doses 1.43 (1.32–1.56) 1.26 (1.08–1.46) 1.24 (1.06–1.45) 1.06 (0.99–1.14)
6–17 doses 1.58 (1.47–1.69) 1.46 (1.28–1.65) 1.16 (1.00–1.35) 1.04 (0.96–1.13)
≥ 18 doses 1.67 (1.56–1.78) 1.58 (1.33–1.87) 1.62 (1.32–2.01) 1.36 (1.16–1.58)
GnRH, gonadotropin-releasing hormone; aHR, adjusted hazard ratio; CI, conﬁdence interval.
aHR: hazard ratio using Cox regression adjusting for age at diagnosis, race, history of bone-related complications, presence of comorbidities, tumor grade,
clinical T stage, and primary treatment.
*Referent group: patients not receiving any androgen deprivation therapy.
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contrast, the even higher fracture rate in men on long-
term therapy, which persists after discontinuation,
may represent the additional effect of a profound re-
duction in bone mineral density.
There is still controversy about whether to pre-
scribe long-term (2 to 3 years) or shorter (6month)
courses for men with locally advanced or high-risk
disease with an indication for adjuvant ADT coupled
with radiotherapy. Although in the clinical trial
setting a longer duration of ADT leads to better
overall and prostate-cancer-speciﬁc survival,28 our
ﬁndings suggest that it would also be associated with
a higher and persistent risk of fracture, as compared
with a shorter course of therapy. Because even short
courses of adjuvant ADT with radiation improve
overall and prostate-cancer-speciﬁc survival,29 men
with a medical history that places them at a high risk
of fracture may wish to consider shorter courses of
ADT to limit that risk.
The excess in the death rates observed among men with
non-metastatic prostate cancer who experience a fracture
is consistent with other hospital- and population-based
investigations of fracture andmortality.30–35 The incidence
of hip fracture in the Medicare population has declined
amongmen in the past decade, as has its associatedmortal-
ity.36 However, both the absolute and relative mortality
risk rates associated with hip fracture are higher among
men compared with women.30,33,34 Risk of death is great-
est in the days and weeks following fracture; however, it
can remain elevated for months and even years.30,31 There
is continued concern about increasedmortality due to non-
prostate-cancer-related causes among patients on ADT,
particularly among men with a history of cardiovascular
disease.37–39 Our results indicate that fracture also contri-
butes to the excess in non-cancer mortality.
There are limitations worth noting in the current
investigation. Confounding by indication is an im-
portant concern in observational studies examining
the effect of treatment on an outcome.40 Our ﬁnd-
ings indicate that ADT was used more frequently
among prostate cancer patients with aggressive-grade
and distant-stage disease. Because the presence of
bony metastases increases fracture risk independently
of treatment,41 we stratiﬁed analyses and examined the
associations with ADT separately among patients with
and without evidence of metastatic disease, either at
the time of diagnosis or at any point over follow-up.
The observed hazard ratios associated with use of
GnRH agonists were similar between groups for both
any fracture and hospitalized fractures. In addition, the
potential for residual confounding is an important con-
sideration stemming from the observational nature of
the investigation and the lack of complete information
on all confounding factors. Therefore, our adjustment
for comorbidities and available confounding variables
in the analysis is likely incomplete.
Medicare data are limited to some degree due to the
potential for missing information on services that are
either not covered by Medicare or not billed to Medi-
care. For this reason, we excluded patients participat-
ing in an HMO in the 12months prior to diagnosis
and censored patients at the time of any change or loss
in Medicare coverage over the course of study. The ex-
clusion of HMO enrollees may limit the generalizabil-
ity of our ﬁndings because HMO enrollees tend to be
younger and healthier than Medicare beneﬁciaries.42
A comparison of the baseline characteristics of
patients excluded for incomplete Medicare coverage
with those included in the analysis indicated that dis-
tributions were similar between groups (results not
shown). An assessment of the representativeness of
SEER patients included in the SEER–Medicare data-
base with the elderly US population indicates that al-
though the age and gender distribution is comparable,
a greater proportion of SEER–Medicare patients be-
long to other minority (non-Black, non-White) groups
and reside in urban areas.42 Last, these ﬁndings are not
necessarily generalizable to patients diagnosed with
prostate cancer before the age of 65 years.
CONCLUSIONS
This study reconﬁrms the link between ADT and frac-
ture incidence in elderly men with prostate cancer.
Moreover, our results also indicate a reduction in frac-
ture rates with an increasing amount of time since last
use, irrespective of the cumulative dose, among men
on GnRH agonists. Because our investigation also
shows an association between fracture and mortality in
these men, it is particularly important for clinicians to
communicate the beneﬁts and possible risks of andro-
gen deprivation to patients and review strategies to re-
duce the potential adverse consequences of therapy.
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KEY POINTS
• Fracture is a recognized consequence of ADT
use; however, the mortality risk associated with
fracture in men with prostate cancer has never
been estimated in a large-scale investigation.
• Conditional on cumulative dose, the risk of frac-
ture associated with ADT use in elderly men with
prostate cancer declines with an increasing num-
ber of months since last use of a GnRH agonist, a
ﬁnding not previously reported.
• Our ﬁndings suggest that careful monitoring of
elderly patients on ADT is crucial, and continu-
ous, long-term use may have serious adverse
consequences for these men.
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